8-KEarnings & ResultsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (May 5, 2010)

Filed May 5, 2010For Securities:ALNY

Summary

This 8-K filing from Alnylam Pharmaceuticals, Inc. on May 5, 2010, primarily announces the company's financial results for the first quarter ended March 31, 2010. While the full details of the financial performance are contained within the furnished press release (Exhibit 99.1), this report serves as notification of the announcement. Investors should refer to the press release for specific revenue figures, net income or loss, research and development expenses, and any forward-looking guidance provided by the company.

Key Highlights

  • 1Announcement of Q1 2010 financial results.
  • 2Financial results for the quarter ended March 31, 2010, were publicly disclosed.
  • 3The full press release containing the financial results is furnished as Exhibit 99.1.
  • 4This filing is made under Item 2.02 (Results of Operations and Financial Condition).
  • 5Information furnished under Item 2.02 is not considered 'filed' for purposes of Section 18 of the Exchange Act.
  • 6The company's principal executive offices are located in Cambridge, MA.

Frequently Asked Questions

The main purpose of this 8-K filing is to announce Alnylam Pharmaceuticals, Inc.'s financial results for the first quarter ended March 31, 2010. The detailed financial information is provided in an attached press release.

The specific financial details for the quarter ended March 31, 2010, are contained in the press release dated May 5, 2010, which is furnished as Exhibit 99.1 to this 8-K filing.

No, the information provided in this 8-K filing, specifically the financial results announced in the press release, is furnished and not deemed 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934, nor is it incorporated by reference into other SEC filings unless specifically stated.

While this filing focuses on financial results, Alnylam Pharmaceuticals is a biotechnology company. Filings like this typically accompany updates on their drug development pipeline, clinical trial progress, and financial health, which are crucial for investors in the pharmaceutical sector.